Healthcare Stock: How Asia’s Largest Dialysis Company Is Scaling with Efficiency and Reach

Synopsis: NephroPlus, Asia’s largest dialysis network, operates 520+ clinics across 325+ cities, serving 36,000+ patients globally. With over 50% share of India’s organised dialysis market, strong EBITDA margins, and an asset-light model, it combines scale, efficiency, and patient-centric care to drive domestic dominance and international expansion.

Nephrocare Health Services Limited (NephroPlus) has carved a niche for itself as the largest dialysis network in India and Asia, revolutionising the way renal care is provided. Today, the company boasts of over 520 clinics across the globe, covering 325+ cities, and serves over 36,000 patients. It has achieved a dominant presence across both metro and Tier II/III cities, with almost 78% of its Indian clinics located in the latter. 

With a market cap of Rs 5,659 crore, the shares of Nephrocare Health Services Ltd are trading at Rs 564. The shares are trading at a PE of 72, whereas their industry’s PE is at 29, and they have given a return of more than 25% since its listing in December 2025.

Dominant Scale with Strong Financial Performance

It enjoys over 50% market share of the organised dialysis market in India. Additionally, NephroPlus is the fifth largest dialysis network across the globe by the number of treatments conducted. In the first nine months of FY26, NephroPlus achieved a revenue from operations of Rs 733.2 crore with an adjusted EBITDA margin of 23.9%. It achieved a   pre-tax ROCE of 24.7%.

Strategic Growth and Sustainable Business Model

NephroPlus has achieved market leadership by growing its footprint in Tier II and Tier III cities, where quality dialysis facilities were not available until now. It has established a strong presence by opening almost 78% of its Indian operations in Tier II and Tier III cities. This strategy has enabled the company to achieve rapid growth with lower capital costs. Notably, NephroPlus operates the largest dialysis clinic across the globe with 165 beds in Tashkent, Uzbekistan, which was won through a global tender under the PPP route.

The company’s business model is highly efficient from a capital perspective, which has enabled the company to achieve high profitability while growing rapidly. With an increase in diabetes and high blood pressure cases contributing to future growth in dialysis needs, NephroPlus is poised to achieve strong growth while maintaining high profitability and financial discipline.

Asset-Light Model Driving Global Expansion

The revenues from international operations are contributing an increasing proportion of the overall revenues. A major point of differentiation is its asset-light and capital-efficient business model. Close to 52% of its clinics operate on a revenue-sharing model, which reduces capital costs while providing a steady inflow of patients. Its cost leadership strategy involves centralised procurement models, operational protocols, biomedical staff, and training academies, which give them high margins even while offering low prices.

However, the real driver behind NephroPlus is its strong patient-centric philosophy. Co-founder Kamal Shah, who has been on dialysis for over 28 years himself, has built a mission around making dialysis patients feel like “guests”. It has built clinical protocols, technology adoption, standardised treatment systems, and global accreditations to achieve this while growing rapidly.

Dialysis is a recurring process for patients who need life-sustaining treatment regularly. With an increasing incidence of diabetes and hypertension in India, the tailwinds for the business are strong. With the backing of marquee investors and an experienced team, NephroPlus is at an exciting juncture of being the largest dialysis network in India and Asia, with strong international relevance.

Financials

The revenue from operations for the company stood at Rs 260 crore in Q3 FY26 compared to the Q3 FY25 revenue of Rs 197 crore, up by about 32 per cent YoY. Similarly, the net profit stood at Rs 32 crore in Q3 FY26, up compared to the Rs 20 crore profit in Q3 FY25.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Healthcare Stock: How Asia’s Largest Dialysis Company Is Scaling with Efficiency and Reach appeared first on Trade Brains.